Ahava has announced that its research and development (R&D) findings for its Dermud skincare range have been published in one of the world’s most respected medical journals Experimental Dermatology and presented at a congress on skin cancer in Israel.
Ahava’s conclusion, published on the Experimental Dermatology website stated: “Our results clearly show that Dermud has protective, anti-oxidant and anti-inflammatory properties that can antagonize biological effects of UVB irradiation in skin. It may therefore be able to reduce skin photodamage and photoageing, and more generally to reduce oxidative stress and inflammation in skin pathologies.”
The results were published in January 2009, and were also presented at an international dermatologist’s conference, the 12th World Congress On ‘Cancers of the Skin’, held in Israel in May.
The event offers dermatologists, plastic surgeons and oncologists the opportunity to interact with a distinguished international faculty to exchange information on the latest advances in skin cancer diagnosis, treatment, prevention and research.
The international faculty of physicians and scientists, renowned experts in the skin cancer topics being covered, is drawn from medical centers, teaching hospitals and government agencies worldwide. Approximately 1,000 participants from around the world attended the congress.
Matoyla Kollaras, Director, Ahava Australia, said of the achievement:
“It is indeed a rare privilege that a skincare company not only has their research published by a highly respected dermatological journal but that their research is also represented at a world congress normally only reserved for the scientific and medical establishment. This is the highest honour that can be bestowed on a skincare company and it strongly reflects our company’s philosophy of committed efforts and investment in research, development and testing to study the therapeutic effectiveness of minerals on the skin and skin disease in conjunction with leading international experts and scientific institutes. Furthermore, it also represents Ahava Dead Sea laboratories’ professional accomplishments and invaluable contributions to the fields of skincare, skin science and dermatology. From years of positive feedback and anecdotal evidence, we always knew that Ahava Dermud was an extremely credible and highly therapeutic product range, now however we also have the scientific evidence to support these claims.
“[We have opened] a new and independent skin and cosmetics laboratory in Ein Gedi, Israel. This laboratory is owned and operated as a partnership between Ahava Dead Sea Laboratories and Megilot Regional Council. The lab will be managed by Ahava’s R&D team and professor Milner of the Hebrew University in Jerusalem. This project received a budget and large support from leading European funds in the field of skin research. Lastly, our chief chemist Dr. Ze’evi Maor has been appointed as the Chairman of the Israeli panel of all cosmetic manufacturers. We congratulate him on this honoured appointment.”